EGFR and lung adenocarcinoma: In our study, we used shallow whole-genome plasma sequencing to evaluate SCNAs of resistance-related genes in ctDNA of EGFR-mutated lung adenocarcinoma patients who had developed the T790M mutation, progressed after treatment with first- or second-generation EGFR TKIs and who were subsequently treated with osimertinib.